... for BreMortalityast Cancer (95% CrI)NNI to Prevent 1 Breast Cancer Death (95% CrI) 20 02 Review (age 65-74y); Humphrey, et al, 20 02 2,3 Malmo and Swedish 2- Ctrialsounty 2 0.78 (0. 62- 0.99) ... Overdiagnosis 20 Key Question 2b. What are the harms associated with CBE? 22 Key Question 2c. What are the harms associated with BSE? 22 Chapter 4. Discussion 23 Summary 23 Limitations 24 Future ... fair quality (Table 2) . 2 For women age 40-49 years, results of the 20 02 meta-analysis indicated a relative risk forbreastcancer mortality of 0.85 (95% CrI, 0.73-0.99) for women randomly...
... treatment forbreastcancer in Norway: comparative analysis of cancer registry data. BMJ 20 11;343:d46 92. 20 . NHS cancer screening programmes. BASO Breast Audit 1999 /20 00. www.cancerscreening.nhs.uk/breastscreen/publications.html ... background for our information in this leaflet below. SCREENING FORBREASTCANCER WITH MAMMOGRAPHY What are the benefits and harms of attending a screening programme forbreast cancer? ... accounts for most of the observed breastcancer specifi c mortality reductions in Australian women since the national screening program began in 1991. BreastCancer Res Treat. Epub 20 11 Sep 29 ....
... more precise molecular classification of breast tumors.BioMed CentralJournal of Biology 20 08, 77::6Published: 22 February 20 08Journal of Biology 20 08, 77::6 (doi:10.1186/jbiol67) The ... understood breastcancer heterogeneitybetter. Two recent papers in Genome Biology from thelaboratories of Carlos Caldas [1] and Eric Miska [2] usemolecular methods to classify breast cancers ... tumorigenicity in breast cancer cells [14] and also invasion and metastasis[15,16]. They are thought to be important in oncogenesis(see [17,18] for reviews).6 .2 Journal of Biology 20 08, Volume...
... localizedestrogen receptors in human breast cancer. Cancer Res 1990,50 12: 3545-3550.9. British Breast Group: Assessment of response to treatment in advanced breast cancer. Lancet 1974, 2: 38-39.10. Hayward ... estradiol hypersensitivity in human breastcancer cells. J ClinEndocrinol Metab 1995, 8010 :29 18 -29 25.15. SOLE trial Newsletter No 8, March 20 11. [http://www.breastinternationalgroup.org/LinkClick.aspx?fileticket=dmcZc0avwBc%3d&tabid =23 41].doi:10.1186/1477-7819-9-101Cite ... Surgical Oncology 20 11, 9:101http://www.wjso.com/content/9/1/101Page 2 of 4RESEARC H Open AccessClinical relevance of “withdrawal therapy” as aform of hormonal manipulation forbreast cancer Amit...